Kevin Feeley Sells 3,728 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction on Monday, December 16th. The stock was sold at an average price of $76.75, for a total transaction of $286,124.00. Following the transaction, the chief financial officer now directly owns 28,200 shares in the company, valued at $2,164,350. This represents a 11.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The stock was sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $18,248.40.

GeneDx Stock Up 2.8 %

WGS stock opened at $77.40 on Friday. The stock has a fifty day moving average of $72.46 and a 200-day moving average of $47.35. GeneDx Holdings Corp. has a fifty-two week low of $2.47 and a fifty-two week high of $89.11. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -24.89 and a beta of 2.03. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.25. The firm had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company’s revenue was up 44.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.82) earnings per share. As a group, equities research analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on WGS shares. Wells Fargo & Company upped their price objective on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group increased their price target on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, Craig Hallum lifted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $59.33.

Institutional Investors Weigh In On GeneDx

Hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new position in shares of GeneDx in the second quarter worth $34,000. nVerses Capital LLC purchased a new stake in GeneDx during the 2nd quarter worth about $50,000. CWM LLC bought a new position in GeneDx in the 3rd quarter worth about $89,000. SG Americas Securities LLC purchased a new position in GeneDx during the 3rd quarter valued at about $198,000. Finally, Point72 DIFC Ltd bought a new stake in shares of GeneDx during the third quarter valued at about $220,000. Institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.